{"schema_version":"secwatch.filing_event.v1","accession":"0001087294-26-000076","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2026-11-10T22:06:04+00:00","discovered_at":"2026-11-10T22:08:00.314183+00:00","generated_at":"2026-11-10T22:08:08.444644+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cumberland posts Q3 net income of $77.8M on Apotex divestiture gain; plans ifetroban NDA in DMD","bullets":["Net income of $77.8M in Q3 2026, driven by the gain on divestiture of commercial brands to Apotex Health, whose $100M strategic transaction closed July 1, 2026.","Cash and equivalents of $80.6M at September 30, 2026; total assets ~$114M, liabilities $42M and shareholders' equity $73M.","Will submit an NDA for ifetroban in DMD cardiomyopathy after a fall pre-NDA meeting; FDA granted a rolling review and conditionally accepted DYSCORBAN as the name.","Phase 2 FIGHT DMD showed a 5.4 percentage point LVEF improvement (p=0.002) in the high-dose group; safety database exceeds 1,400 subjects across ~30 studies.","Phase 2a ASSIST-SSc top-line: ifetroban generally well tolerated, no drug-related serious AEs over 12 months; Cumberland to submit the study report to FDA, SSc decision pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001087294-26-000076","json":"https://secwatch.observer/filing/0001087294-26-000076.json","markdown":"https://secwatch.observer/filing/0001087294-26-000076.md","text":"https://secwatch.observer/filing/0001087294-26-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000076/0001087294-26-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000108729426000076/cpix-20261110.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T22:08:08.444644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}